Bengaluru, India; January 21, 2021:
Biocon Biologics Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that it has inducted Professor Peter Piot to its Board as an Independent Director. Professor Piot, MD, PhD is the Director of the London School of Hygiene & Tropical Medicine and the Handa Professor of Global Health.
Ms Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said: “I welcome Professor Peter Piot to the Biocon Biologics board. He brings years of scientific expertise, long experience in public health interventions and policy framing on major health issues. His thought leadership and invaluable experience in global healthcare will greatly guide our actions in building Biocon Biologics into an innovative global leader in biosimilars committed to delivering affordable access to life saving Biologics.”
On his decision to join the Biocon Biologics board, Professor Peter Piot said: “I am delighted to join dynamic Biocon Biologics and its vital mission of bringing the products of innovation to those who can benefit from them. The world over governments are challenged to contain the spiralling healthcare costs and companies like Biocon Biologics are committed to pursue the path of innovation that enables affordable access to patients globally and in turn helps healthcare systems lower their spends. With several exciting biosimilar molecules in its pipeline, I believe Biocon Biologics has the potential to be truly disruptive in addressing a global need for high quality, affordable biosimilar therapies to treat chronic diseases like diabetes and cancer and save many lives.”
Professor Piot has been appointed to the board of Biocon Biologics Limited for a period of three years starting January 21, 2021.
Professor Peter Piot was initially trained in infectious diseases and medical microbiology, with original contributions in epidemiology, bacteriology, virology, and public health policy interventions mostly in low- and middle-income countries. He is connected to extensive science networks across all continents.
Professor Piot was part of the team that isolated the Ebola virus in Zaire in 1976. He also led pioneering research on HIV/AIDS, women’s health and infectious diseases, mostly in Africa. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations from 1995 until 2008, bringing AIDS to the forefront of the world’s agenda, and ensuring access to life saving antiretroviral medicines.
He has a broad and long term understanding of strategy development and implementation; leadership of both a large inter-governmental organization and of academic institutions; and policy development in health, science, biotechnology, and international development. He has authored over 600 scientific publications and 16 books, including his memoir “No Time to Lose”. He is the recipient of the Calderone Prize, the Hideyo Noguchi Africa Prize for Medical Research, the Prince Mahidol Award for Public Health, the Canada Gairdner Global Health Award and the Robert Koch Gold Medal, and was a 2014 Time Person of the Year “The Ebola Fighters”.
Biocon Biologics proudly welcomes him to the Board.
About Biocon Biologics Limited:
Biocon Biologics Limited, a subsidiary of Biocon Limited, is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world. Building on the four pillars of Patients, People, Partners and Business, Biocon Biologics is committed to transforming healthcare and transforming lives. Biocon Biologics is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. Five molecules from Biocon Biologics’ portfolio have been taken from lab to market, of which three have been commercialized in developed markets like United States, EU, Australia, Canada and Japan. With a team of over 4800 people Biocon Biologics aspires to transform healthcare through affordable innovative solutions as well as impact 5 million patients’ lives by FY 22.
Follow-us on Twitter: @BioconBiologics